Navigation Links
Potential gene therapy for Sickle cell disease

Sickle cell disease (SCD) is an autosomal recessive disorder caused by mutations in hemoglobin (HBB) that deform red blood cells. A small number of patients have been successfully treated with allogeneic hematopoietic stem cell (HSC) transplantation; however, there are several drawbacks and complications associated with this procedure, including graft vs. host disease and long-term immune suppression. Many of complications could potentially be avoided by the use of autologous HSC transplant, which uses patient cells that have been treated genetically modified to replace defective hemoglobin. In this issue of the Journal of Clinical Investigation, Zulema Romero and colleagues investigated the utility of a genetic vector encoding a human hemoglobin gene engineered to impede sickle hemoglobin and prevent the sickling of red blood cells. The vector was used to efficiently transduce bone marrow cells from SCD patients and the transduced cells were successfully transplanted into immunocompromised mice, suggesting that this method could potentially be used to treat SCD.


Contact: Jillian Hurst
Journal of Clinical Investigation

Page: 1

Related biology technology :

1. Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria
2. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
3. Carnegie Mellon study reveals potential of manganese in neutralizing deadly Shiga toxin
4. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
5. Carbon capture and storage -- new research from UKERC shows tough road ahead to realize potential
6. Researchers Find Potential Link Between Drinking Alcohol And Breast Cancer
7. Golden potential for gold thin films
8. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
9. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
10. Welcome to BIO-Poland Explore Our Potential
11. AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... globally touring exhibition Jurassic World: The Exhibition, opening in March 2016 at Melbourne ... on a worldwide tour including several North American tour dates. The Exhibition is ...
(Date:11/30/2015)... 2015  HUYA Bioscience International, the leader in accelerating ... innovations, today announced it has signed a Memorandum of ... foster collaboration between KDDF and HUYA with the ultimate ... products for the global market. ... new innovative preclinical and clinical stage compounds. The company ...
(Date:11/30/2015)... Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced today ... independent director, and the Company welcomes Neil Woodford,s ... a recent anonymous internet report on NW Bio.  The ... Linda Powers stated, "We agree with Mr. ...
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris , qui ... Paris , qui s,est tenu du ... leader de l,innovation biométrique, a inventé le premier scanner ... sur la même surface de balayage. Jusqu,ici, deux scanners ... les empreintes digitales. Désormais, un seul scanner est en ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
Breaking Biology News(10 mins):